Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Venetoclax and pegcrisantaspase for complex karyotype acute myeloid leukemia.
Emadi A, Kapadia B, Bollino D, Bhandary B, Baer MR, Niyongere S, Strovel ET, Kaizer H, Chang E, Choi EY, Ma X, Tighe KM, Carter-Cooper B, Moses BS, Civin CI, Mahurkar A, Shetty AC, Gartenhaus RB, Kamangar F, Lapidus RG. Emadi A, et al. Among authors: niyongere s. Leukemia. 2021 Jul;35(7):1907-1924. doi: 10.1038/s41375-020-01080-6. Epub 2020 Nov 16. Leukemia. 2021. PMID: 33199836 Free PMC article.
PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition-Dependent GSK-3β-Mediated c-Myc and Pim-1 Proteasomal Degradation.
Scarpa M, Singh P, Bailey CM, Lee JK, Kapoor S, Lapidus RG, Niyongere S, Sangodkar J, Wang Y, Perrotti D, Narla G, Baer MR. Scarpa M, et al. Among authors: niyongere s. Mol Cancer Ther. 2021 Apr;20(4):676-690. doi: 10.1158/1535-7163.MCT-20-0663. Epub 2021 Feb 10. Mol Cancer Ther. 2021. PMID: 33568357 Free PMC article.
Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimens.
Kashanian SM, Holtzman NG, Patzke CL, Cornu J, Duffy A, Koka M, Niyongere S, Duong VH, Baer MR, Apata J, Kamangar F, Emadi A. Kashanian SM, et al. Among authors: niyongere s. Cancer Chemother Pharmacol. 2021 Jun;87(6):817-826. doi: 10.1007/s00280-021-04252-y. Epub 2021 Mar 7. Cancer Chemother Pharmacol. 2021. PMID: 33677674
Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia.
Baer MR, Kogan AA, Bentzen SM, Mi T, Lapidus RG, Duong VH, Emadi A, Niyongere S, O'Connell CL, Youngblood BA, Baylin SB, Rassool FV. Baer MR, et al. Among authors: niyongere s. Clin Cancer Res. 2022 Apr 1;28(7):1313-1322. doi: 10.1158/1078-0432.CCR-21-3729. Clin Cancer Res. 2022. PMID: 35091444 Free PMC article. Clinical Trial.
Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study.
Mustafa Ali MK, Corley EM, Alharthy H, Kline KAF, Law JY, Lee ST, Niyongere S, Duong VH, Emadi A, Baer MR. Mustafa Ali MK, et al. Among authors: niyongere s. Front Oncol. 2022 Mar 31;12:858202. doi: 10.3389/fonc.2022.858202. eCollection 2022. Front Oncol. 2022. PMID: 35433414 Free PMC article.
Therapy-related B-lymphoblastic leukemia after multiple myeloma.
Kallen ME, Koka R, Singh ZN, Ning Y, Kocoglu MH, Badros AZ, Niyongere S, Duong VH, Emadi A, Baer MR. Kallen ME, et al. Among authors: niyongere s. Leuk Res Rep. 2022 Nov 1;18:100358. doi: 10.1016/j.lrr.2022.100358. eCollection 2022. Leuk Res Rep. 2022. PMID: 36353199 Free PMC article.
26 results